LAB NEWS
- July 2024: Pete presents lab work on epigenetic and epitranscriptomic sequencing at the Illumina Singapore R&D and manufacturing center – home to more than 75% of the world’s NGS sequencing machines and supplies.
- July 2024: The Dedon Lab wishes a fond farewell to Boon Chong Goh as he sets off on the big adventure of launching his own company, ArrowBiome. Wishing him all success!
- June 2024: Pete Dedon was interviewed by Rick Woychik, the Director of NIEHS, where he spoke about the microbiome's influence on human health.
-23 May 2024: Michelle Mitchener prominently featured in the SMART Newsletter!
-21 February 2024: The Dedon Lab welcomes Chemistry graduate student Maysa Illamanova!
-31 October 2023: The United States Patent and Trademark Office issued US Patent No. 11,802,311 for work pioneered in the Dedon Lab entitled METHODS OF QUANTIFYING RNA AND DNA VARIANTS THROUGH SEQUENCING EMPLOYING PHOSPHOROTHIOATES.
-23 October 2023: Pete Dedon spoke at the MIT Aging Brain Initiative Symposium about the pathology of amyloid plaques and tau protein fibrillary tangles in neurodegenerative diseases, and how aberrant modifications of transfer RNA (tRNA) and silent mutations of codons could play a role.
-20 August 2023: The Dedon Lab welcomes BE graduate student Abby McShane!
-11 Jul 2023: Wei Lin’s discovery of a new stress signaling system that enables bacterial cells to adapt and protect themselves against the immune system and certain antibiotics as published in Nature Communications. Covered at News-Medical.net and at Medical Channel Asia.
-17 Jun 2022: Principal Research Scientist Boon Chong Goh made a presentation on Antimicrobial Resistance at TEDxPSBAAcademy.
-8 Jun 2023: Shane Byrne and the Proteomax team were chosen from among 600 entrants for the final-three pitch in the $1M Temasek Liveability Challenge in Singapore. See Shane’s formal pitch at the Liveability Challenge Grand Finale, and watch his brief elevator pitch.
-23 May 2023: In a publication in JAC-Antimicrobial Resistance, Rifaximin potentiates clarithromycin against Mycobacterium abscessus in vitro and in zebrafish , Dr. Boon Chong Goh in the Dedon Lab discovered a combination of FDA-approved antibiotics that synergizes to kill antibiotic-resistant Mycobacterium abscessus infections. Macrolide antibiotics such as clarithromycin are the cornerstone of treatment for these non-tuberculous mycobacterial infections (NTM), but antibiotic resistance is increasing rapidly, leading to incurable pulmonary infections. The newly discovered antibiotic combination offers hope for treating drug-resistant NTMs and clinical development is underway. The story was covered in a Channel News Asia (CNA) live studio interview with lead author, Dr. Boon Chong Goh, and it also appeared in MIT News, Medical Xpress, Pharmiweb, Pharma Advancement, World Pharma Today, and BioSpectrum Asia.
-31 Jan 2023: Pete Dedon was elected as a fellow of the American Association for the Advancement of Science.
|